查詢結果分析
來源資料
相關文獻
- Short-Course Chemotherapy for Isoniazid-Resistant Pulmonary Tuberculosis
- 非小細胞肺癌之化學治療及其抗藥性
- 癌症化學治療中多元性抗藥性的調節
- 肺結核病人化學治療後的營養評估
- 臨床化學治療產生抗藥性之新觀點:基因擴增在抗藥性腫瘤中所扮演角色
- Fluoroquinolones經驗療法對肺結核之影響
- 動機式會談於一位無意圖服藥多重抗藥性肺結核病人
- 談癌症治療的抗藥性
- The Effects of Ciprofloxacin on Chest Radiographic Regression in Patients with Drug Intolerance or Resistant Tuberculosis
- 肺結核病化學治療之新觀念
頁籤選單縮合
題 名 | Short-Course Chemotherapy for Isoniazid-Resistant Pulmonary Tuberculosis=Isoniazid抗藥性肺結核的短程化學治療 |
---|---|
作 者 | 白冠壬; 余明治; 索任; 江振源; 姜義新; 林道平; 陸坤泰; | 書刊名 | 臺灣醫學會雜誌 |
卷 期 | 97:4 1998.04[民87.04] |
頁 次 | 頁278-282 |
分類號 | 415.2773 |
關鍵詞 | 抗藥性; 肺結核; 化學治療; Mycobacterium tuberculosis; Isoniazid-resistant pulmonary tuberculosis; Short-course chemotherapy; |
語 文 | 英文(English) |
英文摘要 | Standard short-course chemotherapy including isoniazid, rifampicin, pyrazinamide, and ethambutol has been the recommended treatment for tuberculosis in Taiwan since November 1990. The effectiveness of this treatment was evaluated retrospectively in 108 patients with isolates resistant to isoniazid alone and 115 patients with drug-susceptible pulmonary tuberculosis diagnosed anti treated at the Taiwan Provincial Chronic Disease Control Bureau from November 1990 through December 1995. The success rate of treatment was 94.4% in patients with isoniazid-resistant Mycobacterium tuberculosis strains, which was not significantly different from the 97.4% rate in patients with susceptible strains. Of the patients treated successfully, no bacteriologic relapse was found in 97 patients with isoniazid-resistant strains or 103 patients with drug-susceptible strains 12 months after the end of chemotherapy. No significant advantage in treatment outcome was found in patients infected with isoniazid-resistant strains who received chemotherapy for more than 6 months (successful treatment rate, 95.0% vs 92.8%), but the failure rate was higher in patients with a previous history of antituberculosis therapy (17.6% vs 3.3%). We conclude that short- course chemotherapy is effective for isoniazid-resistant pulmonary tuberculosis and that there is no significant difference in treatment outcome between patients with or without isoniazid-resistant disease. |
本系統中英文摘要資訊取自各篇刊載內容。